We rank companies based on fund manager, research analyst and news sentiment

Adial Pharmaceuticals


About: Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Employees: 7

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

210% more capital invested

Capital invested by funds: $158K [Q3] → $491K (+$333K) [Q4]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

67% more funds holding

Funds holding: 9 [Q3] → 15 (+6) [Q4]

17.0% more ownership

Funds ownership: 4.67% [Q3] → 21.67% (+17.0%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ADIL.

Financial journalist opinion

Based on 4 articles about ADIL published over the past 30 days